2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 585

The Role of Genetic Polymorphisms on the Response to Methotrexate Variations Among Rheumatoid Arthritis Patients in Saudi Arabia
Abstract Number: 306

The Role of Inflammation in the Evolution of MRI Erosions in the Feet of Patients with Early RA
Abstract Number: 734

The Role of Micro-RNA 142-3p Expression in Lupus Nephritis in an Egyptian Cohort
Abstract Number: 1433

The Role of Patient and Parental Resilience in Amplified Musculoskeletal Pain Syndrome
Abstract Number: 1360

The Role of Personality in Patients with Knee Osteoarthritis
Abstract Number: 2380

The Safety Profile of Adalimumab across Geographic Regions and Dosing Administrations Among Patients with Juvenile Idiopathic Arthritis Enrolled in a Registry
Abstract Number: 1541

The Safety Profile of Iguratimod in Real Clinical Practice: Analysis of 491 Patients with Rheumatoid Arthritis
Abstract Number: 587

The Superiority of a Treat to Target Strategy over Conventional Treatment with Fixed Csdmard and Corticosteroids: A Multi-Centre Randomized Controlled Trial in RA Patients with Inadequate Response to Conventional Synthetic Dmards, and a New Therapy with Certolizumab Pegol
Abstract Number: 2403

The Therapeutic Alliance Is Associated with a Better Therapeutic Adherence in Children with Juvenile Idiopathic Arthritis: Results of a French Multicenter Study
Abstract Number: 1055

The TLR-4 Inhibitor 6-Shogaol As a Treatment in Osteoarthritis Trough the Modulation of Chondrocyte Hypertrophy and Matrix Calcification
Abstract Number: 310

The Trajectory of Grade 1 Erosions in the Feet of Patients with Early RA
Abstract Number: 2620

The Treatment Choices and Response for a Psoriatic Arthritis Inception Cohort
Abstract Number: 2165

The Trend of Utilization of Therapeutic Plasmapheresis Among Select Rheumatologic Diseases
Abstract Number: 2482

The Use of Any Conventional Synthetic DMARD Is Associated with Better Indexes of the Physical Component Evaluated By 12-Item Short-Form Health Survey : Analysis of a Cohort of RA Patients
Abstract Number: 1199

The Use of Musculoskeletal Ultrasound to Assess Remission in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].